How many employees does Theapharma have?

As of Jul 01, 2024, the latest employee count at Theapharma is 9.

Is Theapharma a funded company?

Theapharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Theapharma rank among its competitors?

Theapharma ranks 2574th amongst 2656 active competitors, of which 903 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Theapharma?

Theapharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Theapharma - 2026 Company Profile & Competitors

Theapharma is an unfunded company. It operates as a Manufacturer of preservative free eye care and ocular health products. Theapharma has not raised any funding yet. The company has 2656 active competitors, including 903 funded and 680 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Manufacturer of preservative free eye care and ocular health products. Offerings include eyelid hygiene solutions, lubricating eye drops for dryness, and nutritional supplements formulated for visual support. These treatments address various therapeutic areas such as allergy, inflammation, infection, and surgical recovery. Products are developed to maintain ocular health through formulations that minimize irritation and support the visual system.

Website: www.theapharma.ie/
Social

Key Metrics

Stage

Unfunded

Ranked

2574^th among 2656 active competitors

Employee Count

9 as on Jul 01, 2024

Similar Companies

Viridian Therapeutics & 290 more

View Theapharma's full profile

Theapharma has not raised any funding rounds yet.

Theapharma's employee count trend

Theapharma has 9 employees as of Jul 24. Here is Theapharma's employee count trend over the years:

Uncover Theapharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Theapharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Theapharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
2574th	Theapharma Unfunded	Manufacturer of preservative free eye care and ocular health products	-	-	19/100